Clinical Trial

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Name: Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma — clinical trial record (NCT07725380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.

Trial Details

NCT Number	NCT07725380
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: National Pediatric Cancer Foundation, Healx USA, Inc
Conditions	Sarcoma, Osteosarcoma
Enrollment	74 participants
Start Date	2026-07-15
Primary Completion	2031-08 (estimated)
Study Completion	2031-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-24